Synergistic Effect of Curcumin in Combination with Anticancer Agents in Human Retinoblastoma Cancer Cell Lines

References

• Joseph R, Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001;10:699–703
   PubMed Web of Science ®Google Scholar
• Squire J, Gallie BL, Phillips RA. A detailed analysis of chromosomal changes in heritable and non-heritable retinoblastoma. Hum Genet 1985;70:291–301
   PubMed Web of Science ®Google Scholar
• Souza Filho JP, Martins MC, Caissie AL, Torres VL, Fernandes LH, Erwenne CM, et al. Relationship between histopathological features of chemotherapy treated retinoblastoma and P-glycoprotein expression. Clin Exp 2005;33:279–284
   Web of Science ®Google Scholar
• Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry 2000;65:95–106
   PubMed Web of Science ®Google Scholar
• Krishnakumar S, Mallikarjuna K, Desai N, Muthialu A, Venkatesan N, Sundaram A, et al. Multidrug resistance proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. BJO 2004;88:1521–1526
   Web of Science ®Google Scholar
• Chan HSL, DeBoer G, Thiessen JJ, Budning A, Kingston JE, O’Brien JM, et al. Combining cyclosporine with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res 1996;2:1499–1508
   PubMed Web of Science ®Google Scholar
• Eckstein LA, Van Quill KR, Bui SK, Uusitalo MS, O’Brien JM. Cyclosporin A inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells. Invest Ophthalmol Vis Sci 2005;46:782–790
   PubMed Web of Science ®Google Scholar
• Chantada GL, Doz F, Orjuela M, Qaddoumi I, Sitorus RS, Kepak T, et al. International Retinoblastoma Staging Working Group. World disparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group. Pediatr Blood Cancer 2008;50:692–694
   PubMed Web of Science ®Google Scholar
• Dorai T, Aggarwal BB. Role of chemopreventive agents in cancer therapy. Cancer Lett 2004;215:129–140
   PubMed Web of Science ®Google Scholar
• Dillman RO. Rationales for combining chemotherapy and biotherapy in the treatment of cancer. Mol Biother 1990;2:201–207
   PubMedGoogle Scholar
• Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann N Y Acad Sci 2005;1056:206–217
   PubMed Web of Science ®Google Scholar
• Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 2010;62:919–930
   PubMed Web of Science ®Google Scholar
• Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of the golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 2012;39:283–299
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23:363–398
   PubMed Web of Science ®Google Scholar
• Du B, Jiang L, Xia Q, Zhong L. Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy 2006;52:23–28
   PubMed Web of Science ®Google Scholar
• Weir NM, Selvendiran K, Kutala VK, Tong L, Vishwanath S, Rajaram M. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 2007;6:178–184
   PubMed Web of Science ®Google Scholar
• Jung EM, Lim JH, Lee TJ, Park JW, Choi KS, Kwon TK. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis 2005;26:1905–1913
   PubMed Web of Science ®Google Scholar
• Gessner PK. Isobolographic analysis of interactions: an update on applications and utility. Toxicology 1995;105:161–179
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 1983;4:450–454
   Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27–55
   PubMedGoogle Scholar
• Chou J, Chou TC. Computerized simulation of dose reduction index (DRI) in synergistic drug combinations. Pharmacologist 1988;30:A231
   Google Scholar
• Chignell CF, Bilski P, Reszka KJ, Motten AG, Sik RH, Dahl TA. Spectral and photochemical properties of curcumin. Photochem Photobiol 1994;59:295–302
   PubMed Web of Science ®Google Scholar
• Kunwar A, Barik A, Mishra B, Rathinasamy K, Pandey R, Priyadarsini KI. Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochim Biophys Acta 2008;1780:673–679
   PubMed Web of Science ®Google Scholar
• Thiyagarajan S, Thirumalai K, Nirmala S, Biswas J, Krishnakumar S. Effect of curcumin on lung resistance-related protein (LRP) in retinoblastoma cells. Curr Eye Res 2009;34:845–851
   PubMed Web of Science ®Google Scholar
• Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004;10:7994–8004
   PubMed Web of Science ®Google Scholar
• Dillman RO. Rationales for combining chemotherapy and biotherapy in the treatment of cancer. Mol Biother 1990;2:201–207
   PubMedGoogle Scholar
• Beevers CS, Li F, Liu L, Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer 2006;119:757–764
   PubMed Web of Science ®Google Scholar
• Mimeault M, Batra SK. Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin Med 2011;6:1–19
   PubMedGoogle Scholar
• Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10:6847–6854
   PubMed Web of Science ®Google Scholar
• Sreenivasan S, Satyabaarathi R, Umashankar V, Krishnakumar S. In vitro and in silico studies on inhibitory effects of curcumin on multidrug resistance associated protein (MRP1) in retinoblastoma cells. Bioinformation 2012;8:13–19
   PubMedGoogle Scholar
• Das M, Sahoo SK. Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS One 2012;7:e32920
   PubMed Web of Science ®Google Scholar
• Harbottle A, Daly AK, Atherton K, Campbell FC. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int J Cancer 2001;92:777–783
   PubMed Web of Science ®Google Scholar
• Hosseinzadeh L, Behravan J, Mosaffa F, Bahrami G, Bahrami AR, Karimi G. Effect of curcumin on doxorubicin-induced cytotoxicity in H9c2 cardiomyoblast cells. Iran J Basic Med Sc 2010;14:49–56
   Web of Science ®Google Scholar
• Bava SV, Sreekanth CN, Thulasidasan AK, Anto NP, Cheriyan VT, Puliyappadamba VT, et al. Akt is upstream and MAPKs are downstream of NF-κB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. Int J Biochem Cell Biol 2011;43:331–341
   PubMed Web of Science ®Google Scholar
• Altenburg JD, Bieberich AA, Terry C, Harvey KA, Vanhorn JF, Xu Z, et al. A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone. BMC Cancer 2011;11:149
   PubMed Web of Science ®Google Scholar
• Andjelkovic T, Pesic M, Bankovic J, Tanic N, Markovic ID, Ruzdijic S. Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R). Cancer Biol Ther 2008;7:1024–1032
   PubMed Web of Science ®Google Scholar
• Sun HD, Ma L, Hu XC, Zhang TD. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integr Chin West Med 1992;12:170–171
   Google Scholar
• Shim JS, Lee HJ, Park S, Cha BG, Chang HR. Curcumin-induced apoptosis of A-431 cells involves caspase-3 activation. J Biochem Mol Biol 2001;34:189–193
   Google Scholar
• Lev-Ari S, Strier L, Kazanov D, Elkayam O, Lichtenberg D, Caspi D, et al. Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells. Rheumatology 2006;45:171–177
   PubMed Web of Science ®Google Scholar
• Mahida JP, Antczak C, Decarlo D, Champ KG, Francis JH, Marr B, et al. A synergetic screening approach with companion effector for combination therapy: application to retinoblastoma. PLoS One 2013;8:e59156
   PubMed Web of Science ®Google Scholar